Table 2 Univariate analysis for the association between each factor and increased retinal pigment epithelial atrophic area (mm²) during the follow-up period of three years

Age (years)

0.014*

 ≦69

42

1.21 (4.00)

 70-79

34

1.72 (3.98)

 ≧80

24

2.10 (3.97)

Gender

0.671†

 Female

48

1.67 (4.25)

 Male

52

1.71 (4.96)

Baseline decimal VA

0.024*

 ≧0.5

70

1.65 (5.08)

 0.2 - 0.4

20

2.44 (3.51)

 ≦0.1

10

3.58 (3.15)

PCV lesion area (DA)

0.001*

 ≦1

29

1.34 (3.79)

  > 1 to ≦2

39

1.45 (3.88)

  > 2 to 4

17

2.08 (3.92)

  > 4

15

2.57 (3.94)

PED at baseline

0.576†

 No

68

1.58 (4.33)

 Yes

32

1.83 (4.36)

Hemorrhage at baseline

0.639†

 No

78

1.60 (4.15)

 Yes

22

1.77 (3.85)

Area of RPE atrophy at baseline (DA)

0.003*

 Incident

16

0.55 (0.35)

 Prevalent

84

1.92 (5.47)

  ≦0.5

44

1.53 (2.95)

   > 0.5 to 1

20

2.07 (3.12)

   > 1

20

2.59 (3.92)

Area of RPE atrophy in fellow eye at baseline (DA)

0.967*

 ≦0.5

39

1.55 (3.41)

  > 0.5

61

1.77 (4.07)

Location of PCV lesion

0.928†

 Subfoveal

88

1.70 (5.24)

 Not subfoveal

12

1.65 (3.95)

Intraretinal fluid at baseline

0.657‡

 None

11

1.73 (3.46)

 Not subfoveal

6

2.08 (2.15)

 Subfovea

83

1.67 (4.64)

Subretinal fluid at baseline

0.687‡

 None

76

1.67 (3.31)

 Not subfoveal

6

1.72 (3.62)

 Subfovea

18

1.86 (3.93)

Number of IVR during 3-year follow-up period

0.336*

 1-5

8

1.69 (2.71)

 6-10

36

1.68 (3.86)

 11-15

42

1.70 (4.25)

 ≧16

14

1.66 (2.25)

Polypoidal lesions three years after the first IVR

0.871†

 Detection

78

1.68 (4.45)

 No detection

22

1.72 (4.73)

Decimal VA three years after the first IVR

0.016*

 ≧0.5

78

1.39 (4.83)

 0.2 - 0.4

15

2.44 (3.86)

 ≦0.1

7

3.31 (2.29)